ImmunomeIMNM
Recorded

Immunome 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration26 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Michael SchmidtSenior Biotech Analyst

Discussion with Clay Siegall, CEO of Immunome. My name is Michael Schmidt, Senior Biotech Analyst with Guggenheim, and I am really looking forward to this. Clay, welcome. Thanks for joining us.

Clay SiegallCEO

Thanks for inviting me to your conference.

Michael SchmidtSenior Biotech Analyst

Clay, obviously, you have a lot going on at Immunome. You have varegacestat started from the FDA. You have an ADC pipeline and the radioligand therapy in the clinic as well. As you think about the next 12 months for the company, what are your key focus areas as you take the company into this next stage?

Clay SiegallCEO

Clearly, varegacestat would come first. We have an action date or PDUFA date from FDA at the end of April in 2027. So we are excited to get that onto the market. We are well-prepared commercially, well-prepared manufacturing, and working hard at that. Also, over the next 12 months with varegacestat, we are working really hard with the European Medicines Agency. We submitted and got validated there, which is sort of like getting filed in the U.S., and they are equivalent. We are working hard with the regulators in the U.S. and Europe. We are also doing the requisite meetings and clinical work we need to do in Japan. Also, we are working with potential commercial distributors, et cetera, in other territories. So we are looking at this as a global product and doing everything we can to get this to patients in need once we get approval.

Clay SiegallCEO

That is going on. We also have a number of clinical trials that we are pursuing with varegacestat that we will talk more about in the coming times to see if we could broaden out our labels. So varegacestat represents something very important to us and our first commercial product.

Clay SiegallCEO

Yeah, go ahead. Okay. Over the next 12 months, I would say the one other big thing would be putting out a lot of clinical data on our many ADCs and really validating our new technology, which we think is state-of-the-art, one of the best, if not the best, ADC technologies out there, fixing many of the problems that were in ADCs over the last few decades, many of which I propagated.

Clay SiegallCEO

We would like to really do something dramatic and differentiated for patients with ADCs looking into the future. You will hear a lot of clinical data starting with ASH, which is next month.

Michael SchmidtSenior Biotech Analyst

On varegacestat, how is the product going to be positioned in the desmoid tumor market? Obviously, there is a similar drug already on the market. What are the key focus areas as you detail that product next year to physicians?

Clay SiegallCEO

Mm-hmm. Our product, varegacestat, outperforms the current product on the market in every way you could look at the product. It has a higher response rate. It is once-a-day dosing. It is very effective on pain relief, as we detailed in our presentation. There are many different aspects of it. So it is a premier first-in-class product. When you look at the incident patients, we think that our commercial team will be out there talking to doctors about using this as the first choice in the incident population. There is a prevalent population out there which is much larger than the incident population. The prevalent population is something that not all patients come in for therapy each year. The incident population is about 1,600 in the U.S. each year, about the same in the EMA.

Clay SiegallCEO

When you look at the prevalent population, there is over 30,000 patients with desmoid in the U.S. Now, about 10,000, 11,000 of them come into therapy each year based on medical records, and they are looking for something. It is usually to combat pain, because they have pain, which pain is correlated with tumor growth. They want something. Over the years, docs have been giving them things like radiation or off-label drugs like SUTENT. Only a few years ago, the very first drug ever approved for desmoid was nirogacestat. It gave another opportunity for patients. Our drug, we believe all the data is just so much better. It is such an improved therapeutic agent, largely because it has much better pharmacokinetics, and that is really the underlying reason why this drug is much better. So, we think that that is a great opportunity for all the incident and prevalent patients.

Clay SiegallCEO

We are going to go out there and try to do the best we can in representing patients and giving them opportunity to get the best possible outcome they can.

Michael SchmidtSenior Biotech Analyst

Yeah. Any learnings from the nirogacestat launch that you could implement or that you could leverage as you implement the launch next year? Talk about how launch-ready are you and how much more commercial build is necessary to support the launch next year?

Clay SiegallCEO

Yeah. What I can say is, looking at a distance at what happened with nirogacestat, I do have to say it was a time where SpringWorks, there was rumors in the Wall Street Journal they were going to get acquired, and then ended up getting acquired months later. It is hard to launch a drug while you are in the middle of an acquisition. So, I will give them that there are logistical issues with that. So, that is one thing. We do not have that. We are very focused on it. I think another thing is we are very focused on medical affairs and connecting with doctors. I have launched many drugs in my career, and medical affairs is critical to having a successful launch. We have the best medical affairs team that we can have. A lot of them came from Seagen, the leadership came from Seagen.

Clay SiegallCEO

I have known them for a long, long period of time, and they did fantastic work and continue to. So I am very pleased with our ability to hit the ground running based on medical affairs. As far as the commercial team, our commercial leadership is Roee Shahar, and he launched two drugs at Seagen. He is a superstar commercial guy, and we are very well positioned to go forward with our commercial team. Our head of manufacturing, Phil Tsai, also came from Seagen, where he literally made every product Seagen had, including the small molecule TUKYSA, which is, in a sense, similar because it is an oral drug to varegacestat, as well as all our ADCs. So I think we are, while we are a small company and we are only a little more than three years old, we are an extremely experienced company.

Clay SiegallCEO

I think that launching a drug for us, for most small companies, is hard. I remember launching the first drug at Seagen, and you are a little bit like a deer in headlights when you do it. After launching many drugs now, we have a very strong playbook and experienced people. So I feel very confident we are going to get out there and get this medicine around to patients.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day